Repurposing empagliflozin for children with Duchenne muscular dystrophy and heart problems
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial studies whether a medicine called empagliflozin, currently used for diabetes, can help improve heart function in children with Duchenne muscular dystrophy who also have heart muscle weakness. The medicine is given as a pill and aims to slow down the heart damage so children can feel better for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child or teen between 6 and 18 years old
- Diagnosed with Duchenne muscular dystrophy and related heart problems (cardiomyopathy)
- Currently taking medication for heart failure
- Able to have a cardiac MRI without general anesthesia
- No diabetes or conditions that cause low blood sugar
- Weight at least 15 kg (about 33 pounds)
- No recent major surgery, blood transfusion, or upcoming heart surgery
- Not taking part in another clinical trial right now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
Hear when a new DMD-associated Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.